Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 942-252-2 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Following daily oral gavage to male and female Sprague‑Dawley rats, for 2 weeks before mating, during mating, gestation and until Day 13p.p., at dose levels of 100, 300 and 1000 mg/kg/day, the No Observed Adverse Effect Level (NOAEL) for parental toxicity was considered to be 1000 mg/kg/day based on the absence of adverse findings at this high-dose level.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 11 April to ... 2019
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Details on species / strain selection:
- Sprague-Dawley, RjHan:SD (CD®)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Janvier, Le Genest-Saint-Isle, France
- Females (if applicable) nulliparous and non-pregnant: yes
- Age at study initiation: on the first day of treatment, the males were approximately 10 weeks old and the females were approximately 11 weeks old
- Weight at study initiation: on the first day of treatment, the males had a mean body weight of 424 g (range: 387 g to 453 g) and the females had a mean body weight of 268 g (range: 239 g to 292 g)
- Fasting period before study: no
- Housing: the animals were housed in a barriered rodent unit. F0 animals were individually housed, except during mating (males + females) and lactation (females + pups), in polycarbonate cages (Tecniplast 2154, 940 cm2) with stainless steel lids and containing autoclaved sawdust (Le comptoir des sciures, Meyzieu, France).
- Diet (e.g. ad libitum): All animals had free access to SSNIFF rat/mouse pelleted maintenance diet, batch No. 94340868 (SSNIFF Spezialdiäten GmbH, Soest, Germany), which was distributed weekly.
- Water (e.g. ad libitum): The animals had free access to bottles containing tap water (filtered with a 0.22 µm filter).
- Acclimation period: Males were acclimated to the study conditions for a period of 7 days before treatment. Females were acclimated to the study conditions for a period of 5 days before the beginning of estrous cycle monitoring during the pre-treatment period.
DETAILS OF FOOD AND WATER QUALITY:
The batches of diet, sawdust and wood shavings were analyzed by the suppliers for composition and contaminant levels.
Bacterial and chemical analyses of water are performed regularly by external laboratories. These analyses include the detection of possible contaminants (pesticides and heavy metals). No contaminants were present in the diet, drinking water, sawdust or wood shavings at levels which could be expected to interfere with, or prejudice, the outcome of the study.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 2°C
- Humidity (%): 50 ± 20%
- Air changes (per hr): about 8 to 15 cycles/hour of filtered, non-recycled air.
- Photoperiod (hrs dark / hrs light): 12 h/12 h
IN-LIFE DATES: From: 11 April 2019 To: 3 July 2019 - Route of administration:
- oral: gavage
- Details on route of administration:
- The dose formulations were administered by gavage, using a plastic syringe fitted with a plastic gavage tube, once a day, at approximately the same time.
- Vehicle:
- water
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
The test item was prepared as an emulsion in the vehicle according to the procedure described below:
- weigh the required quantity of test item directly into a gauged flask,
- complete to final weight with vehicle.
Concentration of the dose formulatrion were the following: 10, 30 and 100 mg/mL.
Test item dose formulations were prepared on the days of treatment. A constant dosage volume of 10 mL/kg/day was used. Control animals (group 1) received the vehicle only.
The quantity of the dose formulation administered to each animal was adjusted according to the most recently recorded body weight.
The dose formulations were maintained under delivery condition (at room temperature) throughout the administration procedure.
The control dose formulation was stirred just before administration and the test item dose formulations for at least 15 minutes before administration. The formulations were maintained under continuous magnetic stirring throughout the administration procedure.
VEHICLE : Water - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Chemical analysis of the dose formulations was performed by High Performance Liquid Chromatography with UV detection (HPLC/UV). A sample was taken from control and test item dose formulations and analyzed using the validated method on formulations used in Weeks 1, 3 and 7 (Acceptance criteria: Measured concentration = nominal concentration ± 15%).
- Duration of treatment / exposure:
- The dose formulations were administered daily according to the following schedule:
- in the males: 2 weeks before mating, during the mating period (until evidence of mating), until euthanasia (at least 4 weeks in total)
- in the females:at least 2 weeks before mating, during the mating period (until evidence of mating), during gestation, during lactation until Day 13 p.p. inclusive, until euthanasia for any females with no delivery. - Frequency of treatment:
- daily
- Dose / conc.:
- 100 mg/kg bw/day (nominal)
- Dose / conc.:
- 300 mg/kg bw/day (nominal)
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- 10 animals/sex/dose level
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale:
The dose levels were selected in agreement with the Sponsor, on the basis of a 2 week preliminary study where males and females were dosed at 100, 300 or 1000 mg/kg/day for 14 days. In this study, there were no premature deaths, no clinical signs, no effects on food consumption or body weight, and no test item related organ weight differences or gross changes. Therefore, 1000 mg/kg/day was selected as the high-dose level. The low-dose and mid dose were selected using a ratio representing approximately a 3-fold interval (i.e. 100 and 300 mg/kg/day).
- Rationale for animal assignment (if not random): Not applicable
- Fasting period before blood sampling for clinical biochemistry: Yes: Prior to blood sampling, the animals were deprived of food for an overnight period of at least 14 hours
- Rationale for selecting satellite groups: Not applicable
- Post-exposure recovery period in satellite groups: Not applicable
- Section schedule rationale (if not random): Not applicable - Positive control:
- Not applicable
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Not specified
MORBIDITY AND MORTALITY: Each animal was checked for mortality and morbidity once a day before the treatment period and at least twice a day during the treatment period, including weekends and public holidays.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Detailed clinical examinations were performed on all animals once before the beginning of the treatment period and then once a week until the end of the study. Observations included (but were not limited to) changes in the skin, fur, eyes, mucous membranes, occurrence of secretions and excretions and autonomic activity (e.g. lacrimation, piloerection, pupil size, unusual respiratory pattern). Changes in gait, posture and response to handling as well as the presence of clonic or tonic movements, stereotypes (e.g. excessive grooming, repetitive circling) or bizarre behavior (e.g. self mutilation, walking backwards) were also evaluated.
BODY WEIGHT: Yes
- Time schedule for examinations: The body weight of each male was recorded once before the beginning of the treatment period, on the first day of treatment (Day 1), then once a week until euthanasia. The body weight of each female was recorded once before the beginning of the treatment period, on the first day of treatment (Day 1), then once a week until mated, on Days 0, 7, 14 and 20 p.c. (post coitum) (and on the day of euthanasia for any females which did not deliver), and on Days 1, 4, 8 and 13 p.p.
FOOD CONSUMPTION:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
The quantity of food consumed by each male was measured once a week from the first day of treatment until the start of the mating period.
The quantity of food consumed by each female was measured once a week from the first day of treatment until the start of the mating period, during gestation for the intervals Days 0-7, 7-14 and 14-20 p.c. and during lactation for the interval Days 1 4, 4-8 and 8-13 p.p. During the mating period, food consumption was not measured for males or females.
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY/COAGULATION: Yes
- Time schedule for collection of blood: on the day of euthanasia
- Anaesthetic used for blood collection: Yes (light isoflurane anesthesia)
- Animals fasted: Yes (for at least 14 hours)
- How many animals: first five males and lactating females from each group
- Parameters checked in table [1] were examined.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: on the day of euthanasia
- Anaesthetic used for blood collection: Yes (light isoflurane anesthesia)
- Animals fasted: Yes (for at least 14 hours)
- How many animals: first five males and lactating females from each group
- Parameters checked in table [2] were examined.
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations and Dose groups that were examined: The first five males and lactating females from each group euthanized as scheduled were evaluated with a Functional Observation Battery once at the end of the treatment period. For females, this was performed on Day 13 p.p. after euthanasia of the pups.
- Battery of functions tested: The following parameters were assessed and graded:
- in the cage: "touch escape" or ease of removal from the cage,
- in the hand: fur appearance, salivation, lacrimation, piloerection, exophthalmos, reactivity to handling, pupil size (presence of myosis or mydriasis),
- in the standard arena (2-minute recording): grooming, palpebral closure, defecation, urination, tremors, twitches, tonic and clonic convulsions, gait, arousal (hypo- and hyper-activity), posture, stereotypy, behavior, breathing, ataxia and hypotonia.
The following measurements, reflexes and responses were recorded: touch response, forelimb grip strength, pupillary reflex, visual stimulus response, auditory startle reflex, tail pinch response, righting reflex, landing foot splay, at the end of observation: rectal temperature.
Finally, motor activity was measured once by automated infra-red sensor equipment over a 60 minute period.
IMMUNOLOGY: No
OTHER: THYROIDE HORMONES
Blood samples were taken, in the first half of the morning (between 7.5 and 10 am), into tubes containing K3-EDTA as anticoagulant, as follows :
- at termination on Day 14 p.p. from all F0 females (approximately 0.5 mL of blood was collected from the orbital sinus under isoflurane anesthesia),
- at termination from all F0 males (approximately 0.5 mL of blood was collected from the orbital sinus under isoflurane anesthesia).
Blood was centrifuged within 2 hours after sampling (approximately 3000g for 10 minutes at +4°C). The plasma was transferred into 2 separate tubes (at least 125 μL in the first tube and the remaining plasma in the second tube) and frozen at -80°C. The levels of the thyroid hormone (T4) and thyroid stimulating hormone (TSH) were determined respectively by LC-MS/MS or Luminex MAP® technology for F0 males sampled at termination. Plasma samples obtained on Day 14 p.p. from F0 females are kept at -80°C pending possible analysis.
- Sacrifice and pathology:
- GROSS PATHOLOGY: Yes (see table 3)
A complete macroscopic post-mortem examination was performed on all F0 animals. This included examination of the external surfaces, all orifices, the cranial cavity, the external surfaces of the brain and spinal cord, the thoracic, abdominal and pelvic cavities with their associated organs and tissues and the neck with its associated organs and tissues. Special attention was paid to the reproductive organs.
The tissues of F0 animals specified in the Tissue Procedure Table (Table 3)) were preserved in 10% buffered formalin (except for the eyes with optic nerves and Harderian glands, and the testes and epididymides which were fixed in Modified Davidson's fixative).
HISTOPATHOLOGY: Yes (see table 3)
A microscopic examination was performed by the Principal Investigator on:
- all tissues listed in the Tissue Procedure Table from the first five euthanized as scheduled males and lactating females of the control and high-dose groups (groups 1 and 4),
- all macroscopic lesions of all groups.
Special emphasis was paid to the stages of spermatogenesis in the male gonads and histopathology of interstitial testicular cell structure.
Preparation of histological slides (F0 animals) All tissues required for microscopic examination were trimmed based on the RITA guidelines, when applicable (Ruehl-Fehlert et al., 2003; Kittel et al., 2004; Morawietz et al., 2004), embedded in paraffin wax, sectioned at a thickness of approximately four microns and stained with hematoxylin-eosin (except testes and epididymides which were stained with hematoxylin/PAS).
ORGAN WEIGHT: Yes (see Table 3)
The body weight of each F0 animal euthanized as scheduled (after the end of the mating period for males or on Day 14 p.p. for females) was recorded before euthanasia. For these animals, the organs specified in the Tissue Procedure Table were weighed wet as soon as possible after dissection, or after fixation for thyroids with parathyroids (when applicable). The ratio of organ weight to body weight (recorded immediately before euthanasia) was calculated.
- Statistics:
- For body weight, food consumption and reproductive data, Data were compared by one-way analysis of variances and Dunnett test (mean values being considered as normally distributed, variances being considered as homogenous) or by Fisher’s exact probability test (proportions).
For hematology, blood biochemistry, body weight (acclimation), hormones, anogenital distance, nipples/areolae, live birth index(es), sex-ratio and post-implantation loss, CITOX software was used to perform the statistical analysis.
PATHDATA software was used to perform the statistical analysis of organ weight data (level of significance of 0.05 or 0.01) - Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Ptyalism was noted at all doses in males and from 300 mg/kg/day in females (1/10 males at 100 mg/kg; 3/10 males and 2/10 females at 300 mg/kg and 10/10 males and 3/10 females at 1000 mg/kg during the pre-mating period; 4/10 females at 300 mg/kg and 9/10 females at 1000 mg/kg during gestation and 1/10 females at 1000 mg/kg during the lactation period). In females, ptyalism was observed during pre-mating and gestation periods and only once at 1000 mg/kg/day during lactation. The number of affected animals was mainly dose-related, as well as the duration of the effect (ranging from 1 day to half of whole dosing period in some males). This clinical sign was not noticed during detailed clinical observation as part of the Functional Observation Battery, demonstrating that ptyalism was transient after treatment administration. This finding was considered to be test item treatment-related but non-adverse.
- Mortality:
- mortality observed, non-treatment-related
- Description (incidence):
- There were no unscheduled deaths in males and females. One female was euthanized 26 days after the end of the mating period for no delivery. Macroscopic examination revealed that this female was not pregnant.
- Body weight and weight changes:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There were no effect on mean body weight and mean body weight changes (see Table 4).
Statistically significant higher mean body weight gain was noticed between Days 8 and 13 p.p. in lactating females dosed at 100 and 1000 mg/kg/day when compared to controls. Taking into account the lack of dose-relationship, the fact that this was mainly due to 2 control females which lost weight on this interval and the absence of effect on mean body weight at the end of lactation period, this effect was not attributed to the test item treatment. - Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- There were no effects on mean food consumption.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There were no test item-related effects on evaluated hematology and coagulation parameters (see Table 5).
In males, at 1000 mg/kg/day, a slight decrease in fibrinogen level (-12%) was observed. Despite a statistical significance (p<0.01), this was considered to be not toxicologically relevant based on absence of correlation with other parameters related to coagulation and inflammation (platelets, APTT, prothrombin time). In addition, no similar effect was observed in females.
At 300 mg/kg/day, a slight increase in lymphocyte counts (+33%) was observed. Despite a statistical significance (p<0.05), this was considered to be not toxicologically relevant since this was not dose-related mainly due to one animal (P24811) and, due to coagulation in tubes from 2 animals, impairing the analysis, results were obtained on 3 animals instead of 5. No similar effect was observed in females.
In females, at 1000 mg/kg/day, a slight decrease in hemoglobin level (-6%) was observed, correlating with a slightly lower packed cell volume (hematocrit, -8%) when compared to controls. Despite a statistical significance (p<0.05), this was considered to be not toxicologically relevant due to the low magnitude of variation. There was no similar effect in males.
A slight shorteningin APTT (-11%) was observed. Despite a statistical significance (p<0.05), this was considered to be not toxicologically relevant. There was no correlation with other parameters related to coagulation (platelets, fibrinogen, prothrombin time). In addition, no similar effect was observed in males. - Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- In male, a dose dependent increase in total bilirubin level was observed (statistically significant from 300 mg/kg/day) when compared to controls. This effect was not considered test item treatment-related as all the values were of low magnitude and below the validated quantification range, i.e. in a physiological range and there were no concomitant effects on other hepatic function markers (ALAT, ASAT, ALP) or microscopic correlates. A similar effect was not noted in females.
A dose dependent minimal increase of albumin/globulin ratio was observed (statistically significant at 1000 mg/kg/day). This effect was considered test item treatment-related. However, changes were of low magnitude and poorly dose-related in females.
Total cholesterol concentration was slightly decreased at 1000 mg/kg/day when compared to controls ( 27%, p<0.01). This effect was considered test item treatment-related, although without correlation with variations in other markers (TRIG, ALAT, ASAT, ALP) or microscopic correlates. A similar effect was not observed in females.
In females, a slight dose dependent increase in glucose level was noticed when compared to controls (statistically significant at 1000 mg/kg/day, p<0.05). This effect was considered test item treatment-related, however there were no correlation with significant variations in other markers or microscopic correlates. A similar effect was not observed in males (see Table 6). - Urinalysis findings:
- not examined
- Behaviour (functional findings):
- effects observed, treatment-related
- Description (incidence and severity):
- There were no effects of test item treatment on detailed clinical examination as part of the Functional Observation Battery.
There were no effects of test item treatment on reactivity to manipulation and different stimuli.
In female animals, the average number of horizontal movement was dose-dependently reduced when compared to controls (-50% at 1000 mg/kg/day, p<0.05). Since no hypoactivity was noticed neither at Functional Observation Battery nor at routine clinical examination, this effect was considered test item treatment related but non-adverse (see Table 7). - Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Spleen weights were generally increased in females at ≥ 100 mg/kg/day and reached statistical significance at ≥ 300 mg/kg/day. There were no correlating microscopic or hematology findings for these weight increases and therefore the organ weight changes were considered to have unlikely toxicological significance or relationship to test item administration.
In male animals, thymus absolute and relative to body weights were increased in males at 300 mg/kg/day only. Without a test item effect in high dose animals or a histopathological correlate this increase was not considered to have toxicological relevance. Additionally, absolute heart weight was statistically significantly decreased when compared to control animals in males at 1000 mg/kg/day, this very small magnitude change was not accompanied by microscopic or macroscopic effects and was considered to be due to individual variability and not a test item effect.
In female animals, decreased relative to body weight brain weight was observed at ≥ 300 mg/kg/day only and was not associated with a statistically significant increase in absolute brain weight. This very small magnitude decrease did not have a correlating microscopic finding or any clinical evidence, including Functional Observational Battery and motor activity results and was thus considered to have no toxicological relevance. Additionally, a statistically significant increase in absolute adrenal weights was observed for females at 300 mg/kg/day. Without a test item effect in high dose animals or a histopathological correlate, this was considered to have no toxicological relevance and was attributed to expected biological variability for rats of this strain and age (see table 8) - Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- No test article-related gross findings were noted.
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- No test article-related microscopic findings were noted.
- Histopathological findings: neoplastic:
- not examined
- Other effects:
- no effects observed
- Description (incidence and severity):
- Thyroid hormones (T4, TSH): There were no differences in treated F0 males from concurrent control means which could be considered to be test item-related (no dose relationship, no microscopic correlates, no statistical significance and/or slight variations from controls) (see table 9).
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Key result
- Critical effects observed:
- no
- Conclusions:
- The test item, SOPROMINE 1686, was administered daily by oral gavage to male and female Sprague Dawley rats, for 2 weeks before mating, during mating, gestation and until Day 13 p.p., at dose levels of 100, 300 and 1000 mg/kg/day. Based on the experimental conditions and results of this study, the No Observed Adverse Effect Level (NOAEL) for parental toxicity was considered to be 1000 mg/kg/day based on the absence of adverse findings at this high-dose level.
- Executive summary:
The objective of this GLP study was to evaluate the potential toxic effects of the test item,SOPROMINE 1686,following daily oral administration (gavage) to male and female rats from before mating, through mating and, for females, through gestation until Day 13 post-partum (p.p.).
This study provides initial information:
- on the possible health hazards likely to arise from repeated exposure over a relative limited period of time,
- on male and female reproductive performance, such as gonadal function, mating behavior, conception, development of the conceptus and parturition.
The study was performed according to OECD guideline No. 422 and in compliance with GLP.
Methods
Three groups of ten male and ten female Sprague-Dawley rats (F0 animals) received the test item,SOPROMINE 1686(batch No.8230049),daily, by oral administration (gavage), 2 weeks before mating, during mating and, for the males until euthanasia, for the females throughout gestation until Day 13 post‑partum(p.p.) inclusive. The dose levels were 100, 300 and 1000 mg/kg/day. Another group of ten males and ten females received the vehicle (Drinking water treated by reverse osmosis) only and acted as a control group. A constant dosage volume of 10 mL/kg/day was used.
The actual test item concentrations in the dose formulations prepared for use in Weeks 1, 3 and 7 were determined using a validatedHigh Performance Liquid Chromatography with UV detection (HPLC/UV) method.
The F0 animals were checked daily during the dosing period for mortality, morbidity and clinical signs. Detailed clinical observations were performed at least once a week. Body weight and food consumption were recorded once a week during premating, mating (food consumption not during mating), gestation (0, 7, 14 and 20p.c.)and lactation(Days 1, 4, 8 and 13p.p.)periods.
The F0 animals were paired for mating after 2 weeks of treatment and the females were allowed to litter and rear their progeny until Day 13p.p.
A Functional Observation Battery (FOB) including touch response, forelimb grip strength, pupillary reflex, visual stimulus response, auditory startle reflex, tail pinch response, righting reflex, landing foot splay, rectal temperature and motor activity was performed on five F0 animals per sex and group at the end of the treatment period. Analysis of hematology and blood biochemistry parameters was performed from blood samples taken prior to euthanasia from at least five F0 animals per sex and group. Thyroid hormones (T4 and TSH) plasma levels were determined at termination from all F0 males.
The F0 males were euthanized after at least 4 weeks of treatment (Day 30) and the F0 females on Day 14p.p.Final body weights and selected organs weights (adrenals, brain, epididymides, heart, kidneys, liver, pituitary gland, prostate, seminal vesicles, spleen, testes and thymus) were recorded and a complete macroscopicpost‑mortemexamination was performed, with particular attention paid to the reproductive organs. A microscopic examination was performed on long list of organs from five F0 animals per sex in the control and high-dose groups and on all macroscopic lesions.
Results
The test item concentrations were within an acceptable range of variation (± 15% of the nominal concentrations required). No test item was observed in the control dose formulations.
In parental animals, there were no test item-related unscheduled deaths. Transient ptyalism after treatment was noted at all dose levels in males with dose-related incidence and in females from 300 mg/kg/day. Females were affected during pre-mating and gestation periods, but in a lower extent during lactation (1 out of 10 females at 1000 mg/kg/day). This clinical sign was considered to be test item-related and non‑adverse. There were no effects on mean body weight, mean body weight change and mean food consumption. There were no test item-related changes atreactivity to manipulation, to different stimuli and at motor activity evaluation (FOB) at any dose level, except a non-adverse dose-related decrease in horizontal movement in females.Hematology and coagulation parameter evaluation did not reveal differences from controls after test item administration. There were no differences between T4 and TSH levels from test item-treated and control male animals.
At pathology examination, there were no gross findings, microscopic findings or organ weight changes attributable to administration of SOPROMINE 1686.
Conclusion
Based on the experimental conditions and results of this study,the No Observed Adverse Effect Level (NOAEL) for parental toxicity was considered to be 1000 mg/kg/day based on the absence of adverse findings at this high-dose level.
Reference
Chemical analysis of the dose formulations:
Test item test concentrations in the administered dose formulations were analyzed in Weeks 01, 03 and 07. The test item concentrations remained within an acceptable range of variation (-7.8% to +3.4%) when compared to the nominal values (± 15% required). No test item was observed in the control dose formulations.
Table 4: Mean body weight (g) and mean body weight change (g)
Sex |
Male |
Female |
||||||
Dose level (mg/kg/day) |
0 |
100 |
300 |
1000 |
0 |
100 |
300 |
1000 |
Pre-mating (female) or whole study (males) |
||||||||
Day 15 |
511 |
499 |
504 |
493 |
278 |
277 |
284 |
283 |
% vs. controls |
|
-2 |
-1 |
-4 |
|
0 |
+2 |
+2 |
Days 1 - end of period* |
+130 |
+118 |
+126 |
+124 |
+12 |
+10 |
+15 |
+13 |
Gestation |
||||||||
Day 20p.c. |
/ |
/ |
/ |
/ |
421 |
433 |
440 |
436 |
Days 0 - 20p.c. |
/ |
/ |
/ |
/ |
+140 |
+148 |
+152 |
+149 |
Lactation |
||||||||
Day 13p.p. |
/ |
/ |
/ |
/ |
362 |
373 |
377 |
377 |
Days 1 - 13p.p. |
/ |
/ |
/ |
/ |
+36 |
+47 |
+40 |
+44 |
/: not applicable; In bold: body weight change.
*: Day 29 (male animals) or 15 (female animals).
No statistically significant differencesvs.controls.
Table 5: Hematology and coagulation (F0 animals)
Sex |
Male |
Female |
||||||
Dose level (mg/kg/day) |
0 |
100 |
300 |
1000 |
0 |
100 |
300 |
1000 |
Lymphocytes (G/L) |
13.60 |
16.07 |
18.12* |
13.55 |
9.87 |
10.33 |
10.84 |
10.74 |
% vs. controls |
|
+18 |
+33 |
0 |
|
+5 |
+10 |
+9 |
Hemoglobin (g/dL) |
15.6 |
15.9 |
16.7 |
15.8 |
16.2 |
15.7 |
15.9 |
15.2* |
% vs. controls |
|
+2 |
+7 |
+1 |
|
-3 |
-2 |
-6 |
Packed Cell Volume (L/L) |
0.48 |
0.48 |
0.50 |
0.48 |
0.51 |
0.48 |
0.49 |
0.47* |
% vs. controls |
|
0 |
+4 |
0 |
|
-6 |
-4 |
-8 |
MCHC (g/dL) |
32.7 |
33.4 |
33.2 |
33.1 |
32.1 |
33.0* |
32.7 |
32.3 |
% vs. controls |
|
+2 |
+2 |
+1 |
|
+3 |
+2 |
+1 |
Fibrinogen (g/L) |
3.17 |
3.23 |
3.14 |
2.80** |
3.83 |
3.84 |
3.82 |
3.65 |
% vs. controls |
|
2 |
-1 |
-12 |
|
0 |
0 |
-5 |
APTT (s) |
15.5 |
15.1 |
14.6 |
15.5 |
14.5 |
14.3 |
14.3 |
12.9* |
% vs. controls |
|
-3 |
-6 |
0 |
|
-1 |
-1 |
-11 |
MCHC:mean cell hemoglobin concentration, PLT: platelet, APTT: activated partial thromboplastin time.
Statistical significance:*: p<0.05, **: p<0.01.
Table 6: Blood biochemistry (F0 animals)
Sex |
Male |
Female |
||||||
Dose level (mg/kg/day) |
0 |
100 |
300 |
1000 |
0 |
100 |
300 |
1000 |
Total Bilirubin (µmol/L) |
0.17 |
0.53 |
0.80* |
0.84* |
0.71 |
0.62 |
1.01 |
0.51 |
% vs. controls |
|
+212 |
+371 |
+394 |
|
-13 |
+42 |
-28 |
Albumin (g/L) |
36 |
36 |
37 |
35 |
36 |
35 |
36 |
35 |
% vs. controls |
|
0 |
+3 |
-3 |
|
-3 |
0 |
-3 |
Albumin/globulin ratio |
1.95 |
1.99 |
2.05 |
2.08* |
1.94 |
2.11* |
2.06 |
2.09 |
% vs. controls |
|
+2 |
+5 |
+7 |
|
+9 |
+6 |
+8 |
Total cholesterol (mmol/L) |
2.29 |
1.97 |
2.00 |
1.68** |
2.68 |
2.62 |
2.46 |
2.38 |
% vs. controls |
|
-14 |
-13 |
-27 |
|
-2 |
-8 |
-11 |
Glucose (mmol/L) |
7.36 |
7.08 |
6.65 |
7.14 |
6.04 |
6.74 |
6.91 |
7.81* |
% vs. controls |
|
-4 |
-10 |
-3 |
|
+12 |
+14 |
+29 |
ALAT (U/L) |
60 |
57 |
57 |
73 |
75 |
95 |
81 |
124** |
% vs. controls |
|
-5 |
-5 |
+22 |
|
+27 |
+8 |
+65 |
ALAT: alanine aminotransferase,Statistical significance:*: p<0.05, **: p<0.01.
In bold: test item treatment-related.
Table 7: Effects on motor activity
Sex |
Male |
Female |
||||||
Dose level (mg/kg/day) |
0 |
100 |
300 |
1000 |
0 |
100 |
300 |
1000 |
Horizontal movements |
592 |
499 |
611 |
577 |
503 |
409 |
326 |
251* |
% vs. controls |
|
-16 |
+3 |
-3 |
|
-19 |
-35 |
-50 |
Rearing |
188 |
159 |
179 |
209 |
137 |
96 |
111 |
76 |
% vs. controls |
|
-15 |
-5 |
+11 |
|
-30 |
-19 |
-45 |
Statistical significance:*: p<0.05.
Table 8: Summary of main organ weight data - terminal euthanasia (Day 30/Day 14p.p.)
|
Female |
||
Group |
2 |
3 |
4 |
Dose (mg/kg/day) |
100 |
300 |
1000 |
No. animals per group |
10 |
10 |
10 |
Spleen (no. weighed)a |
5 |
5 |
5 |
Absolute value |
18.7 |
29.6* |
40.7* |
% of body weight |
14.1 |
22.1* |
32.0* |
a: all values expressed as percent difference of control group means.
Based upon statistical analysis of group means,values highlighted in bold are significantly different from control group – P =<0.05; refer to data tables in the dedicated report for actual significance levels and tests used.
Table 9: Mean thyroid hormone levels (±Standard Deviation) in F0 males at termination were the following:
Sex |
Male |
|||
Dose level (mg/kg/day) |
0 |
100 |
300 |
1000 |
T4 (ng/mL) |
40.79 (± 7.12) |
35.77 (± 7.16) |
40.02 (± 6.39) |
35.06 (± 3.57) |
|
|
-12 |
-2 |
-14 |
TSH (pg/mL) |
2520 (± 1107) |
2568 (± 1112) |
1965 (± 1182) |
1875 (± 1226) |
|
|
+2 |
-22 |
-26 |
in italic: differences from controls (%).
No statistically significant differencesvs.controls.
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 000 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- OECD TG 422 and GLP compliant study
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
One Klimish 1 study is available. This study was performed according to OECD guideline No. 422 and in compliance with GLP. Three groups of ten male and ten female Sprague-Dawley rats (F0 animals) received the registered substance,daily, by oral administration (gavage), 2 weeks before mating, during mating and, for the males until euthanasia, for the females throughout gestation until Day 13 post‑partum(p.p.) inclusive. The dose levels were 100, 300 and 1000 mg/kg/day. Another group of ten males and ten females received the vehicle (Drinking water) only and acted as a control group. In parental animals, there were no test item-related unscheduled deaths. Transient ptyalism after treatment was noted at all dose levels in males with dose-related incidence and in females from 300 mg/kg/day. Females were affected during pre-mating and gestation periods, but in a lower extent during lactation (1 out of 10 females at 1000 mg/kg/day). This clinical sign was considered to be test item-related and non‑adverse. There were no effects on mean body weight, mean body weight change and mean food consumption. There were no test item-related changes at reactivity to manipulation, to different stimuli and at motor activity evaluation (FOB) at any dose level, except a non-adverse dose-related decrease in horizontal movement in females. Hematology and coagulation parameter evaluation did not reveal differences from controls after test item administration. There were no differences between T4 and TSH levels from test item-treated and control male animals. At pathology examination, there were no gross findings, microscopic findings or organ weight changes attributable to administration of the test item.
In conclusion, the No Observed Adverse Effect Level (NOAEL) for parental toxicity was considered to be 1000 mg/kg/day based on the absence of adverse findings at this high-dose level.
Justification for classification or non-classification
Based on the absence of adverse test item-related effects up to the highest dose of 1000 mg/kg bw/day
in an OECD 422 study performed by the oral route in rats, no classification for STOT-RE hazard category is warranted according to CLP and GHS UN classification criteria.Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.